Amiprilose hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592652

CAS#: 60414-06-4

Description: Amiprilose hydrochloride is an Immunopotentiator.

Chemical Structure

img
Amiprilose hydrochloride
CAS# 60414-06-4
Instruction

Theoretical Analysis

MedKoo Cat#: 592652
Name: Amiprilose hydrochloride
CAS#: 60414-06-4
Chemical Formula: C14H28ClNO6
Exact Mass: 341.16
Molecular Weight: 341.829
Elemental Analysis: C, 49.19; H, 8.26; Cl, 10.37; N, 4.10; O, 28.08

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Amiprilose hydrochloride; Amiprilose HCl

IUPAC/Chemical Name: alpha-D-Glucofuranose, 3-O-(3-(dimethylamino)propyl)-1,2-O-(1-methylethylidene)-, hydrochloride

InChi Key: RJNRORZRFGUAKL-ADMBVFOFSA-N

InChi Code: InChI=1S/C14H27NO6.ClH/c1-14(2)20-12-11(18-7-5-6-15(3)4)10(9(17)8-16)19-13(12)21-14;/h9-13,16-17H,5-8H2,1-4H3;1H/t9-,10-,11+,12-,13-;/m1./s1

SMILES Code: O[C@H](CO)[C@@H](O1)[C@H](OCCCN(C)C)[C@@H](O2)[C@H]1OC2(C)C.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 341.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Linhardt RJ, Baenziger NC, Ronsen B. Structure of amiprilose hydrochloride, a novel anti-inflammatory agent. J Pharm Sci. 1990 Feb;79(2):158-62. PubMed PMID: 2324965.

2: Hevelone JC, Dimitrijevich SD, Gracy RW. Effects of amiprilose hydrochloride on the components of human skin equivalents. In Vitro Cell Dev Biol. 1991 May;27A(5):387-96. PubMed PMID: 2071542.

3: Riskin WG, Gillings DB, Scarlett JA. Amiprilose hydrochloride for rheumatoid arthritis. Ann Intern Med. 1989 Sep 15;111(6):455-65. PubMed PMID: 2672925.

4: Caldwell JR, Furst DE, Smith AL, Clark JA, Bonebrake RA, Gruhn WB, McIlwain HH, Logue CM. Flare during drug withdrawal as a method to support efficacy in rheumatoid arthritis: amiprilose hydrochloride as an example in a double blind, randomized study. J Rheumatol. 1998 Jan;25(1):30-5. PubMed PMID: 9458199.

5: Trentham DE, Fife RS, Carpenter BA, Box JH, Trout R, Lanser ME. Amiprilose hydrochloride for the treatment of rheumatoid arthritis. J Clin Rheumatol. 2000 Feb;6(1):10-8. PubMed PMID: 19078443.

6: Brinckerhoff CE. Decreased cell proliferation and PGE2 production by fibroblasts treated with a modified hexose sugar, amiprilose hydrochloride. Agents Actions. 1990 Jun;30(3-4):322-8. PubMed PMID: 2386107.

7: Siegel CO, Churchill DA, Vu L, Guyton JR, Minor ST, Raizner AE. Amiprilose hydrochloride inhibits porcine aortic smooth muscle cell proliferation in vitro. Artery. 1994;21(2):114-23. PubMed PMID: 7695482.

8: Young MR. Modulation of eicosanoid biosynthesis and inhibition of substrate availability for phospholipase A2 by a modified hexose sugar, amiprilose hydrochloride. Prostaglandins. 1990 Jul;40(1):35-49. PubMed PMID: 2167503.

9: Chang DM. Immunoregulatory effects of a synthetic monosaccharide. Immunopharmacol Immunotoxicol. 1995 Aug;17(3):437-50. PubMed PMID: 8576539.

10: Weinblatt ME, Fraser PA, Anderson R, Coblyn JS, Trentham DE. Diminution of the T8 subset by amiprilose hydrochloride in refractory RA. J Rheumatol. 1987 Aug;14(4):859-60. PubMed PMID: 3499514.

11: Chapman ML, Dimitrijevich SD, Hevelone JC, Goetz D, Cohen J, Wise GE, Gracy RW. Inhibition of psoriatic cell proliferation in in vitro skin models by amiprilose hydrochloride. In Vitro Cell Dev Biol. 1990 Oct;26(10):991-6. PubMed PMID: 2243063.

12: Grinstead WC, Rodgers GP, Mazur W, Cromeens DM, French BA, West MS, Raizner AE. Amiprilose in the prevention of restenosis after coronary intervention in a swine model. Coron Artery Dis. 1993 Mar;4(3):277-81. PubMed PMID: 8269222.

13: Kieval RI, Young CT, Prohazka D, Brinckerhoff CE, Trentham DE. Evaluation of a modified hexose sugar, amiprilose hydrochloride, in experimental models of synovitis. J Rheumatol. 1989 Jan;16(1):67-74. PubMed PMID: 2785600.

14: Wu ST, Benet LZ, Lin ET. Determination of amiprilose in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Sci Appl. 1997 Apr 25;692(1):149-56. PubMed PMID: 9187394.

15: Garrett ER, Van Peer A. Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites. J Pharm Sci. 1983 Sep;72(9):1045-57. PubMed PMID: 6631692.

16: Garrett ER, Van Peer A, Altmayer P, Schuermann W, Lücker P. Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers. J Pharmacokinet Biopharm. 1982 Jun;10(3):247-64. PubMed PMID: 7175698.

17: Merkel PA, Letourneau EN, Polisson RP. Investigational agents for rheumatoid arthritis. Rheum Dis Clin North Am. 1995 Aug;21(3):779-96. Review. PubMed PMID: 8619099.

18: Garrett ER, Van Peer A, Mahrous H, Schuermann W. Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride. J Pharm Sci. 1982 Apr;71(4):387-95. PubMed PMID: 7086643.

19: Kremer JM. Severe rheumatoid arthritis: current options in drug therapy. Geriatrics. 1990 Dec;45(12):43-8. Review. PubMed PMID: 2123816.

20: Erdö F, Török K, Németh Z, Székely JJ, Borsy J, Csányi E. Effect of amprilose on various immunological and inflammatory animal models. Acta Physiol Hung. 1990;75 Suppl:93-4. PubMed PMID: 2371913.